No Data
No Data
Starpharma's DEP Irinotecan Shows Promising Efficacy in Phase 2 Advanced Cancer Trials
Starpharma (ASX: SPL) has announced positive anti-tumour efficacy results from a Phase 2 clinical trial of its lead candidate DEP irinotecan in heavily pre-treated patients with a range of difficult-to-treat advanced and metastatic cancers.
We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth
Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16%
Biopharmaceutical company Starpharma (ASX:SPL) entered into a strategic partnership with healthcare-focused investment firm Medicxi to co-found a new UK-based company called Petalion Therapeutics, aim
Starpharma Asked to Provide More Data for US FDA Approval of Vivagel
Starpharma Holdings (ASX:SPL) said the US Food and Drug Administration has demanded "additional" clinical efficacy data for the regulatory approval of the firm's VivaGel medication. The FDA ruling "do
Starpharma Says DEP Docetaxel Shows Positive Results From Clinical Trial
Starpharma Holdings (ASX:SPL) said DEP docetaxel showed positive results in the phase 2 clinical trial program. The drug demonstrated anti-tumor activity in multiple advanced, metastatic cancers, incl
Even After Rising 42% This Past Week, Starpharma Holdings (ASX:SPL) Shareholders Are Still Down 88% Over the Past Three Years
No Data